CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 2, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) are holding a joint meeting today (scheduled from 8:00 A.M. to 5:00 P.M. ET) to discuss Sage’s New Drug Application (NDA) currently under review for ZULRESSO™ (brexanolone) injection for the treatment of postpartum depression (PPD). The briefing materials can be found on the FDA website at: https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering CNS disorders. Sage's lead product candidate, ZULRESSO™ (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression. For more information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181102005229/en/
Source: Sage Therapeutics
Paul Cox, 617-299-8377
Maureen L. Suda, 585-355-1134